^
    Back
    Association details:
    Biomarker:CD74-ROS1 fusion + TP53 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Thorac Oncol
    Title:

    Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

    Excerpt:
    CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. TP53-co-mutant patients had a significantly shorter median PFS than wild-type patients...ROS1-/TP53-co-aberrant patients had a significantly worse outcome compared to TP53 wild-type patients.
    DOI:
    https://doi.org/10.1016/j.jtho.2019.03.020